Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$18.41
▼ $4.63 (-20.1%)
Market data updated: 10/01 08:44 AM
News analyzed: 10/01/2026
Market Cap
$348.44M
Day Range
$17.70 - $23.03
52-Week Range
$17.31 - $39.60
Beta
—
Next Earnings
—
Support
$17.31
Resistance
$39.60
SCTX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-3.0% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 0/9 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
No notable strengths identified.
Computed directly from the same signals behind the score above — not AI-generated.
Biggest negative driver
Daily volatility (ATR)
ATR: 20.5% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Not enough price history for this symbol to compute a current state.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
37
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
24
Risk
42
Sentiment
68
Fundamental
No data available
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Scribe Therapeutics Inc. has primarily focused on its investor interest and market momentum, particularly tied to Cathie Wood’s ARK Invest’s increased exposure to the biotech firm. The company’s IPO debut and upcoming Phase 1 data for STX-1150 (a potential LDL-C treatment) have drawn attention, as analysts highlight the need for first-half 2027 clinical results to sustain investor confidence. While headlines mention broader biotech trends, Scribe’s specific focus remains clinical progress and strategic positioning amid rising biotech speculation.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Scribe Therapeutics Inc.. News trend score: 68. Reason: 3 of the last 6 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
38
🎯 Conviction (vs. Emotion)
50
Psychology
45
Fundamentals
—
Technical
24
Valuation
—
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
-3%
Market Narrative
40
Fundamental Reality
50
Narrative Gap
-10
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
👥 What the crowd believes
"ARK’s latest portfolio moves spotlighted ... SCTX as the firm increased its biotech exposure"
"STX-1150 Phase 1H27 LDL-C data is key"
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 98/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for SCTX reflects a clash between cyclical optimism and deep caution. Samuel Armstrong Nelson and Charles Mackay’s high scores suggest the stock may be undervalued relative to its cycle or free from speculative frenzy, while Thorstein Veblen and Jack Schwager see it as a disciplined, value-aligned opportunity—even early-to-mid cycle, per Howard Marks. Yet, the majority of methodologies—especially Graham, Fisher, Lynch, and Bagehot—struggle with insufficient data, leaving their frameworks unable to form a definitive view. Meanwhile, the low scores from Livermore, Loeb, and Housel signal red flags: a potential downtrend, excessive risk, or volatility that could deter patient investors, while Malkiel/Bogle’s skepticism leans toward passive strategies over active bets. The contrast underscores whether the stock’s perceived strengths (cycle positioning, growth alignment) outweigh its structural risks or data gaps.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 86
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 80
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 79
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 79
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 46
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 29
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 25
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 47 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 8 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
Not enough trading history for a Wyckoff-style market-structure analysis.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 3 positive, 3 neutral, 0 negative out of the last 6 articles.
Yahoo · 28.9.2026
SeekingAlpha · 27.9.2026
Yahoo · 22.9.2026
Benzinga · 22.9.2026
Benzinga · 22.9.2026
Yahoo · 17.9.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Scribe Therapeutics Inc. (SCTX) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for SCTX specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
SCTX's technical score is 24/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 20.5% of price; MACD histogram is negative — falling momentum; ADX 29.6 — strong trend.
StockIQ has no recorded dividend payment history for SCTX.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 8 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Aghazadeh Behzad | Open Market Purchase | 28.7.2026 | 3,088,888 | +7,905 | $18.25 |
| AH Bio Fund II, L.P. | Conversion of Derivative Security | 27.7.2026 | 0 | -12,150,003 | — |
| ORBIMED ADVISORS LLC | Conversion of Derivative Security | 27.7.2026 | 0 | -2,065,672 | — |
| ORBIMED ADVISORS LLC | Conversion of Derivative Security | 27.7.2026 | 348,825 | +348,825 | — |
| Doudna Jennifer A | Conversion of Derivative Security | 27.7.2026 | 603,547 | +12,511 | — |
| ORBIMED ADVISORS LLC | Open Market Purchase | 27.7.2026 | 1,348,825 | +1,000,000 | $15.00 |
| AH Bio Fund II, L.P. | Open Market Purchase | 27.7.2026 | 2,385,075 | +333,333 | $15.00 |
| AH Bio Fund II, L.P. | Conversion of Derivative Security | 27.7.2026 | 697,650 | +697,650 | — |
| Doudna Jennifer A | Conversion of Derivative Security | 27.7.2026 | 0 | -74,088 | — |
| GORDON CARL L | Conversion of Derivative Security | 27.7.2026 | 0 | -2,065,672 | — |
| GORDON CARL L | Open Market Purchase | 27.7.2026 | 1,348,825 | +1,000,000 | $15.00 |
| AH Bio Fund II, L.P. | Conversion of Derivative Security | 27.7.2026 | 2,051,742 | +2,051,742 | — |
| GORDON CARL L | Conversion of Derivative Security | 27.7.2026 | 348,825 | +348,825 | — |
| Aghazadeh Behzad | Open Market Purchase | 24.7.2026 | 3,030,983 | +2,333,333 | $15.00 |
| Aghazadeh Behzad | Open Market Purchase | 24.7.2026 | 3,080,983 | +50,000 | $22.31 |
| Parrot David | Open Market Purchase | 23.7.2026 | 1,333 | +1,333 | $15.00 |
| GORDON CARL L | Grant/Award from Employer | 23.7.2026 | 14,725 | +14,725 | — |
| Lucas Svetlana | Grant/Award from Employer | 23.7.2026 | 109,426 | +109,426 | — |
| Bleharski Joshua | Grant/Award from Employer | 23.7.2026 | 14,725 | +14,725 | — |
| Lucas Svetlana | Open Market Purchase | 23.7.2026 | 3,000 | +3,000 | $15.00 |
| Aghazadeh Behzad | Grant/Award from Employer | 23.7.2026 | 14,725 | +14,725 | — |
| Oakes Benjamin L. | Grant/Award from Employer | 23.7.2026 | 429,599 | +429,599 | — |
| Oakes Benjamin L. | Grant/Award from Employer | 23.7.2026 | 264,784 | +264,784 | — |
| Watson James Dean | Grant/Award from Employer | 23.7.2026 | 14,725 | +14,725 | — |
| Staahl Brett | Grant/Award from Employer | 23.7.2026 | 19,385 | +19,385 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
790,538 shares short as of 2026-09-15 · vs. 778,191 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
80.6% of trading volume this week was short selling, vs. 78.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology